Seasonal Influenza Vaccine

A Phase III, double-blind, randomised, controlled, multi-country, multi-centre study to evaluate the immunogenicity and safety of GSK Biologicals’ quadrivalent influenza vaccine candidate, GSK2282512A (FLU Q-QIV), compared to GSK Biologicals’ trivalent influenza vaccine Fluarix®, administered intramuscularly to children 6 to 35 months of age.

Register Today!

Trial Information

Trial Duration26 weeks
Number of Visits4
Lead CRCChantelle Jacklin

For additional information
on this trial contact: